Ribociclib in early breast cancer

If ribociclib has a positive effect on overall survival in patients with HR+ HER2- advanced breast cancer, what about early breast cancer? In this international, randomized, open-label Phase 3 trial, patients were randomly assigned to receive ribociclib (400 mg daily for 3 weeks, followed by one week off, for 3 years) plus a non-steroidal aromatase inhibitor (letrozole 2.5 mg daily or anastrozole 1 mg daily for at least 5 years) or a non-steroidal aromatase inhibitor alone. The interim results of the trial are presented here. A significant benefit in terms of invasive disease-free survival was observed with ribociclib compared with the non-steroidal aromatase inhibitor used alone.